BioAge Labs, Inc.

BIOA

Find Out if You Qualify for a Financial Reward by filling out the form below.

Lead Plaintiff Deadline:
March 10, 2025

Days Left:
61

calendar

BioAge Labs, Inc. Form












Class Action Lawsuit List does not share your information with others. There is no cost or obligation for you to submit.

Allegations

According to the complaint, on December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 trial for azelaprag, its lead product candidate, citing safety concerns over elevated liver transaminase levels in participants. This came as a surprise because, at the time of its IPO less than three months earlier, BioAge highlighted azelaprag's potential in patients undergoing obesity therapy with incretin drugs. Following this news, BioAge’s stock price declined from $20.09 per share on December 6, 2024 to $4.65 per share on December 7, 2024.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of BioAge purchased or acquired during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in BioAge during the relevant time frame, you have until March 10, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Active Cases

Ticker Symbol Company Name Join Deadline Join
WOLF Wolfspeed, Inc. January 17, 2025 Join
SUI Sun Communities, Inc. February 10, 2025 Join
SAVA Cassava Sciences, Inc. February 10, 2025 Join
APLT Applied Therapeutics, Inc. February 18, 2025 Join
BIOA BioAge Labs, Inc. March 10, 2025 Join